SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: GlobalData | PRODUCT CODE: 2182603

Cover Image

PUBLISHER: GlobalData | PRODUCT CODE: 2182603

M&A in the Contract Manufacturing Industry: Implications and Outlook - 2026 Edition

PUBLISHED:
PAGES: 45 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 4995
PDF (Site License)
USD 9990
PDF (Global License)
USD 14985

Add to Cart

This report is the sixth edition of our analysis of mergers and acquisitions in the pharmaceutical contract manufacturing industry. It provides strategic bio/pharmaceutical insight on M&A deals involving CMOs and CDMOs.

Scope

This 45-page report gives important, expert insight you won't find in any other source. 11 tables and 18 figures throughout the report illustrate major points and trends. This report is required reading for:

  • CMOs/CDMOs: market trends, strategic planning, competitive intelligence, performance benchmarking
  • Bio/Pharma: supplier performance benchmarking, market trends, competitive intelligence
  • Private equity and stock analysts: target identification and analysis, portfolio company performance benchmarking.

Reasons to Buy

  • Overview of M&A in the Pharma CMO Industry
  • Detailed view of CDMO performance by number of deals, based on GlobalData's Deals database
  • Analysis of M&A and private equity investment by target's specific manufacturing services
Product Code: GDPS0054MAR

Table of Contents

Table of Contents

List of Tables

List of Figures

1 Executive Summary

2 Players

3 Technology Briefing

  • 3.1 Deal types

4 Trends

5 Industry Analysis

  • 5.1 Objectives and methodology
  • 5.2 Overview of M&A activity in 2025
    • 5.2.1 Target characteristics
    • 5.2.2 Acquirer characteristics
    • 5.2.3 Geography
  • 5.3 Target segment close-ups
    • 5.3.1 Multi
    • 5.3.2 API-small molecule
    • 5.3.3 Commercial dose manufacturing
    • 5.3.4 API-biologic
  • 5.4 Deal advisors
    • 5.4.1 Top financial advisors
    • 5.4.2 Top legal advisors
    • 5.4.3 Valuations
    • 5.4.4 Facility acquisitions
  • 5.5 What it means
    • 5.5.1 Slower, considered deal-making in 2025
    • 5.5.2 APAC rising and India leads... for now
    • 5.5.3 Geographic diversification is a business driver
    • 5.5.4 Europe offers benefits, but the UK is off the table, for some CMOs
    • 5.5.5 Private equity investment falls to five-year low
  • 5.6 The outlook for M&A
    • 5.6.1 API-biologic targets

6 Value Chain

7 Companies

8 Appendix

  • 8.1 Methodology
  • 8.2 Further reading
  • 8.3 About the Authors
  • Contact Us
Product Code: GDPS0054MAR

List of Table

List of Tables

  • Table 1: CMO M&A trends, 2025
  • Table 2: Company acquisitions by target service offering and year, 2021-25
  • Table 3: Company acquisitions by target service offering and target ownership, 2025
  • Table 4: Company acquisitions by target service offering and deal region, 2025
  • Table 5: Company acquisitions by target service offering and acquirer ownership, 2025
  • Table 6: Services deals with known transaction value and multiples, 2025
  • Table 7: Facility acquisitions by CMOs, 2025
  • Table 8: Private equity deals, 2025
  • Table 9: Potential targets: API-biologic service providers
  • Table 10: Company acquisitions and private equity deals, 2025
  • Table 11: Further reading

List of Figure

List of Figures

  • Figure 1: Leading acquirers in the global pharma CMO industry, 2025
  • Figure 2: Top M&A trends, 2025
  • Figure 3: CMO M&A activity, 2025
  • Figure 4: CMO M&A activity by year, 2021-25
  • Figure 5: CMO M&A activity percentage change by year, 2022-25
  • Figure 6: Company acquisitions by target service offering, 2025
  • Figure 7: Company acquisitions by target ownership, 2025
  • Figure 8: Company acquisitions by target ownership and service type, 2025
  • Figure 9: Acquisition targets by sophistication of capabilities, 2025
  • Figure 10: Number of acquisitions 2025 by acquirer's core business
  • Figure 11: Number of acquisitions by acquirer's ownership, 2025
  • Figure 12: Number of acquisitions by acquirer's ownership and target service type
  • Figure 13: Number of acquisitions by target country, 2025
  • Figure 14: Dose forms manufactured by acquired manufacturers (all service types), 2025
  • Figure 15: Top financial advisors to company acquisitions, 2025
  • Figure 16: Top legal advisors to company acquisitions, 2025
  • Figure 17: Pharma CMO facility acquisitions, 2025
  • Figure 18: The contract manufacturing value chain
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!